Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients

20 Aug 2015

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Drug Transport and Resistance Mechanisms
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26294332
DOI: 10.1007/s00277-015-2477-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patientsPMID 26294332Read ↗

Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.Semantic proximity Read ↗

Varying responses of PML-RARA with different genetic mutations to arsenic trioxideSemantic proximity Read ↗

Resistance to Arsenic Therapy in Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapseSemantic proximity Read ↗

A Sole p.G391E Mutation in PML::RARA Identified in Relapsed Acute Promyelocytic LeukemiaSemantic proximity Read ↗

PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.Semantic proximity Read ↗

Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia – the occurrence of retinoic acid syndrome is a risk factorSemantic proximity Read ↗

Impact of Simultaneous Presence of Multiple PML-RARA Isoforms on Phenotype in Patients with Acute Promyelocytic Leukaemia.Semantic proximity Read ↗

Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaSemantic proximity Read ↗

Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR methodSemantic proximity Read ↗

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatmentSemantic proximity Read ↗

Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.